FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2470595544> ?p ?o ?g. }

• W2470595544 endingPage "A377" @default.
• W2470595544 startingPage "A376" @default.
• W2470595544 abstract "New oral anticoagulants (NOACs) are available for the treatment and prevention of VTE but evidence on their clinical effectiveness compared with existing treatments is limited. This research compared the clinical effectiveness of dabigatran, rivaroxaban, adjusted standard dose warfarin (warfarin), and low molecular weight heparin (LMWH) in people with active cancer following VTE. This research was conducted during a review of the company’s submission (CS) to the National Institute for Health and Care Excellence (NICE) Single Technology Appraisal programme for the oral direct thrombin inhibitor, dabigatran. Randomised controlled trials (RCTs) for inclusion were identified using the CS for dabigatran (as part of Technology Appraisal [TA]327), and two similar submissions for rivaroxaban (TA261 and TA287). RCTs were assessed for comparability based on patient population, disease severity, and treatments received. A Bayesian MTC was conducted, and fixed and random effects models were explored. Odds ratio (OR) was chosen as the summary statistic for VTE recurrence and major bleed. The network of 9 RCTs formed a “radiating star”. The fixed effects model had the lowest deviance information criterion (DIC) for VTE recurrence and major bleed and so was chosen as the best-fitting model. There was reasonable agreement between the number of unconstrained data points and the residual deviance for both outcomes. Results compared to dabigatran were (OR>1 favours dabigatran): VTE recurrence LMWH OR 0.96 (95% Credible Interval [95%CrI]: 0.15–3.37), rivaroxaban OR 1.29 (95%CrI: 0.12–5.42), warfarin OR 1.87 (95%CrI: 0.31–6.45); major bleed LMWH OR 0.85 (95%CrI: 0.15–2.67), warfarin OR 0.74 (95%CrI: 0.15–2.15). No data were available on major bleed for rivaroxaban in people with active cancer. There were no significant differences in the outcomes evaluated. However, the available evidence suggests that LMWH may have the lowest risk of VTE recurrence in the treatments assessed." @default.
• W2470595544 created "2016-07-22" @default.
• W2470595544 creator A5057607432 @default.
• W2470595544 creator A5063880557 @default.
• W2470595544 creator A5082198761 @default.
• W2470595544 date "2015-11-01" @default.
• W2470595544 modified "2023-09-30" @default.
• W2470595544 title "A Mixed Treatment Comparison (Mtc) to Compare the Efficacy of Anti-Thrombotic Agents in the Acute Treatment of Venous Thromboembolism (Vte) in Patients with Active Cancer" @default.
• W2470595544 doi "https://doi.org/10.1016/j.jval.2015.09.787" @default.
• W2470595544 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26532127" @default.
• W2470595544 hasPublicationYear "2015" @default.
• W2470595544 type Work @default.
• W2470595544 sameAs 2470595544 @default.
• W2470595544 citedByCount "0" @default.
• W2470595544 crossrefType "journal-article" @default.
• W2470595544 hasAuthorship W2470595544A5057607432 @default.
• W2470595544 hasAuthorship W2470595544A5063880557 @default.
• W2470595544 hasAuthorship W2470595544A5082198761 @default.
• W2470595544 hasBestOaLocation W24705955441 @default.
• W2470595544 hasConcept C126322002 @default.
• W2470595544 hasConcept C177713679 @default.
• W2470595544 hasConcept C2776301958 @default.
• W2470595544 hasConcept C2776413415 @default.
• W2470595544 hasConcept C2776710957 @default.
• W2470595544 hasConcept C2778661090 @default.
• W2470595544 hasConcept C2778810321 @default.
• W2470595544 hasConcept C2779161974 @default.
• W2470595544 hasConcept C2908647359 @default.
• W2470595544 hasConcept C71924100 @default.
• W2470595544 hasConcept C99454951 @default.
• W2470595544 hasConceptScore W2470595544C126322002 @default.
• W2470595544 hasConceptScore W2470595544C177713679 @default.
• W2470595544 hasConceptScore W2470595544C2776301958 @default.
• W2470595544 hasConceptScore W2470595544C2776413415 @default.
• W2470595544 hasConceptScore W2470595544C2776710957 @default.
• W2470595544 hasConceptScore W2470595544C2778661090 @default.
• W2470595544 hasConceptScore W2470595544C2778810321 @default.
• W2470595544 hasConceptScore W2470595544C2779161974 @default.
• W2470595544 hasConceptScore W2470595544C2908647359 @default.
• W2470595544 hasConceptScore W2470595544C71924100 @default.
• W2470595544 hasConceptScore W2470595544C99454951 @default.
• W2470595544 hasIssue "7" @default.
• W2470595544 hasLocation W24705955441 @default.
• W2470595544 hasOpenAccess W2470595544 @default.
• W2470595544 hasPrimaryLocation W24705955441 @default.
• W2470595544 hasRelatedWork W1888436343 @default.
• W2470595544 hasRelatedWork W1917089101 @default.
• W2470595544 hasRelatedWork W2074821794 @default.
• W2470595544 hasRelatedWork W2103668926 @default.
• W2470595544 hasRelatedWork W2130149431 @default.
• W2470595544 hasRelatedWork W2167183908 @default.
• W2470595544 hasRelatedWork W2345422643 @default.
• W2470595544 hasRelatedWork W2415661531 @default.
• W2470595544 hasRelatedWork W2810513411 @default.
• W2470595544 hasRelatedWork W2888978342 @default.
• W2470595544 hasVolume "18" @default.
• W2470595544 isParatext "false" @default.
• W2470595544 isRetracted "false" @default.
• W2470595544 magId "2470595544" @default.
• W2470595544 workType "article" @default.